Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Pfizer Inc recalls 1.8...

    Pfizer Inc recalls 1.8 million vials of antibiotics

    Written by Ruby Khatun Khatun Published On 2018-05-24T10:30:12+05:30  |  Updated On 24 May 2018 10:30 AM IST
    Pfizer Inc recalls 1.8 million vials of antibiotics

    New Delhi: Pfizer Inc has recalled over 1.8 million vials of piperacillin and tazobactam, that were manufactured in India, from the US market.


    According to a notification of the US Food and Drug Administration, the product was manufactured by Hospira Healthcare India Private Limited, a Pfizer company, at its plant at Irungattukottai near Chennai for Apotex Corp to be sold in the USA.


    The combination of piperacillin and tazobactam is used to treat different infections caused by bacteria.


    "Piperacillin and tazobactam have been found to contain elevated levels of impurities that may result in decreased potency. The affected product is manufactured by Hospira Inc., a Pfizer Company and distributed in the US market by Apotex Corp," the notification said.


    Apotex Corp. has notified wholesalers and distributor through a letter to arrange for the return of any recalled product.


    Similarly, AuroMedics Pharma LLC, an Aurobindo pharmaceutical subsidiary, has also started a voluntary recall of 77,400 vials of piperacillin and tazobactam.


    The products have been found to contain particulate matter, visible only after reconstitution that was confirmed to be glass within the vial, the FDA said.


    As on May 14, AuroMedics Pharma LLC has not received reports of any adverse effect or identifiable safety concerns attributed to the product, it said.

    antibioticsApotex CorpbacteriacontaminationHospira Healthcare India Private LimitedIndiainfectionsparticulate matterPfizerPfizer Incpiperacillinpiperacillin and tazobactamrecallstazobactamUS Food and Drug AdministrationUS marketvials
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok